Lisata Therapeutics, Inc. (LSTA)
(Delayed Data from NSDQ)
$3.20 USD
+0.06 (1.91%)
Updated Sep 11, 2024 01:47 PM ET
After-Market: $2.98 -0.22 (-6.87%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Cash flow Statements
Fiscal Year End for Lisata Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -20.84 | -54.23 | -27.47 | -8.14 | -19.35 |
Depreciation/Amortization & Depletion | -0.77 | 0.86 | 2.57 | 0.37 | 0.30 |
Net Change from Assets/Liabilities | -0.46 | -0.83 | 0.65 | -2.32 | -1.12 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 2.04 | 33.03 | 2.01 | 1.27 | 1.30 |
Net Cash From Operating Activities | -20.03 | -21.17 | -22.25 | -8.82 | -18.88 |
Property & Equipment | 0.00 | -0.29 | -0.06 | -0.02 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | -3.32 | 0.00 | 0.00 | 0.00 |
Investments | 10.10 | 32.52 | -54.84 | -7.26 | 21.43 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 10.10 | 28.91 | -54.90 | -7.28 | 21.43 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.48 | 0.04 | 85.52 | 18.73 | 1.31 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.09 | -0.27 | -0.25 | -0.15 | -0.13 |
Net Cash from Financing Activities | 0.39 | -0.22 | 85.28 | 18.58 | 1.18 |
Effect of Exchange Rate Changes | -0.02 | -0.01 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -9.56 | 7.51 | 8.14 | 2.48 | 3.73 |
Cash at Beginning of Period | 32.15 | 24.65 | 16.51 | 14.03 | 10.30 |
Cash at End of Period | 22.59 | 32.15 | 24.65 | 16.51 | 14.03 |
Diluted Net EPS | -2.58 | -10.47 | -7.50 | -7.95 | -28.19 |
Fiscal Year End for Lisata Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -10.45 | -5.40 | -20.84 | -15.48 | -10.21 |
Depreciation/Amortization & Depletion | -0.19 | -0.11 | -0.77 | -0.57 | -0.33 |
Net Change from Assets/Liabilities | -2.46 | -2.07 | -0.46 | -1.49 | -3.10 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 0.79 | 0.55 | 2.04 | 1.57 | 1.26 |
Net Cash From Operating Activities | -12.31 | -7.03 | -20.03 | -15.96 | -12.38 |
Property & Equipment | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | -0.10 | -0.10 | 0.00 | 0.00 | 0.00 |
Investments | 18.25 | 6.54 | 10.10 | 15.82 | 3.56 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 18.15 | 6.44 | 10.10 | 15.82 | 3.56 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.03 | 0.00 | 0.48 | 0.45 | 0.45 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.14 | -0.14 | -0.09 | -0.09 | -0.09 |
Net Cash from Financing Activities | -0.11 | -0.14 | 0.39 | 0.36 | 0.37 |
Effect of Exchange Rate Changes | -0.03 | -0.06 | -0.02 | 0.06 | -0.02 |
Net Change In Cash & Equivalents | 5.70 | -0.79 | -9.56 | 0.27 | -8.46 |
Cash at Beginning of Period | 22.59 | 22.59 | 32.15 | 32.15 | 32.15 |
Cash at End of Period | 28.29 | 21.81 | 22.59 | 32.43 | 23.69 |
Diluted Net EPS | -0.61 | -0.65 | -0.66 | -0.65 | -0.50 |